Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome

Renal Failure

Volumn 35, Issue 5, 2013, Pages 738-741

  Enriquez R ^a   Sirvent, A E ^a   Padilla, S ^a   Noguera Pons, R ^a   Andrada, E ^a   Ardoy, F ^a   Millan I ^a   Amoros F ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Amyloidosis; Anakinra; Cinca; Cryopyrin; Muckle wells; Nephrotic syndrome

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMYLOID A PROTEIN; BICARBONATE; C REACTIVE PROTEIN; CHLORIDE; COLCHICINE; CREATININE; FIBRINOGEN; HEMOGLOBIN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE; POTASSIUM; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UREA; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLOIDOSIS; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOINFLAMMATORY DISEASE; BICARBONATE BLOOD LEVEL; BRAIN ATROPHY; CASE REPORT; CHLORIDE BLOOD LEVEL; CINCA SYNDROME; CLUBBING FINGERS; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; EXUDATE; FIBRINOGEN BLOOD LEVEL; FIBROSING ALVEOLITIS; GENE MUTATION; GENETIC ANALYSIS; HEARING AID; HEARING IMPAIRMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMPOTENCE; INFLAMMATORY CELL; KIDNEY BIOPSY; LABORATORY TEST; LEG EDEMA; MALE; MEDICAL HISTORY; MYOPIA; NEPHROTIC SYNDROME; NEUROIMAGING; NEUTROPHIL COUNT; ONSET AGE; PATIENT REFERRAL; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; PLEURA EFFUSION; POLYARTHRITIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; THORACOCENTESIS; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; UVEITIS; VISUAL ACUITY;

AMYLOIDOSIS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME;

EID: 84877850864     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.790300     Document Type: Article

References (23)

1. Neven B, Prieur AM, Quartier dit Maire P. Cryopyrinopathies: Update on pathogenesis and treatment. Nat Clin Pract Rheumatol. 2008;4:481-489
2. Henderson C, Goldbach-Mansky R. Monogenic auto inflammatory diseases: New insights into clinical aspects and pathogenesis. Curr Opin Rheumatol. 2010;22:567-578
3. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/ CINCA. Curr Rheumatol Rep. 2011;13:123-131
4. Dodé C, Le Dû N, Cuisset L, et al. New mutations of CIAS1that are responsible for Muckle-Wells syndrome and familial cold urticaria: A novel mutation underlies both syndromes. Am J Hum Genet. 2002;70:1498-1506 (Pubitemid 34533897)
5. Kümmerle-Deschner JB, Tyrrell PN, Reess F, et al. Risk factors for severe Muckle-Wells syndrome. Arthritis Rheum. 2010;62:3783-3791
6. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-Associated auto inflammatory diseases. Arthritis Rheum. 2002;46:3340-3348 (Pubitemid 35453546)
7. Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56:1273-1285 (Pubitemid 46608652)
8. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused bymutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71:198-203 (Pubitemid 34734724)
9. Aróstegui JI, Aldea A, Modesto C, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent auto inflammatory syndromes associated with the CIAS1/PYPAF1/ NALP3 gene. Arthritis Rheum. 2004;50:4045-4050 (Pubitemid 39643954)
10. Aróstegui JI.Pathophysiologicalmechanismsunderlying cryopyrinassociated periodic syndromes: Genetic and molecular basis and the inflammasome). Med Clin (Barc). 2011;136(Suppl. 1):22-28
11. Granel B, Philip N, Serratrice J, et al. CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes. Dermatology. 2003;206:257-259 (Pubitemid 36407835)
12. Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome-description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13:R196
13. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with auto inflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142:1591-1597 (Pubitemid 44969215)
14. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-2371 (Pubitemid 46883770)
15. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21:1732-1744
16. Neven B, Marvillet I, Terrada C, et al. Long-Term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258-267
17. Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three-And five-year outcomes. Arthritis Rheum. 2012;64:2375-2386
18. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74:85-94 (Pubitemid 36776180)
19. Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: Experiences and explanations. Rheumatol Int. 2012;32:295-299
20. Direz G, Noël N, Guyot C, Toupance O, Salmon JH, Eschard JP. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure. Joint Bone Spine. 2012;79:631
21. Caorsi R, Federici S, Gattorno M. Biologic drugs in auto inflammatory syndromes. Autoimmun Rev. 2012;12:81-86
22. Ter Haar N, Lachmann H, Ozen S, et al. Treatment of auto inflammatory diseases: Results from the Euro fever registry and a literature review. Ann Rheum Dis. 2013;72:678-685
23. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatalonset multisystem inflammatory disease. Arthritis Rheum. 2005;52:1283-1286 (Pubitemid 40530137)